Point72 Asset Management
CLDX icon

Point72 Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Point72 Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100,000
Closed -$3.4M – 2121
2024
Q3 		$3.4M Buy
+100,000
New +$3.81M 0.01% 992

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management's CLDX Position: Q1 2026 in Review

Point72 Asset Management increased its Celldex Therapeutics (CLDX) stake by 84% in Q1 2026, buying an estimated $40.1M and bringing the position to 3,229,939 shares worth $102M. The position accounts for 0.13% of the portfolio, ranked #168.

Point72 Asset Management first reported a position in CLDX in Q1 2021 and has held it in 16 quarters since. The position peaked at $109M in Q4 2023. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Point72 Asset Management held 3,229,939 shares of Celldex Therapeutics worth $102M as of Q1 2026.
  • Point72 Asset Management bought 1,471,582 Celldex Therapeutics shares in Q1 2026, an estimated $40.1M.
  • Celldex Therapeutics made up 0.13% of Point72 Asset Management's portfolio in Q1 2026, its #168 holding.
  • Point72 Asset Management first reported a position in Celldex Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • Point72 Asset Management's Celldex Therapeutics position peaked at $109M in Q4 2023.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.